4.5 Article

Current State of Pediatric Cardio-Oncology: A Review

期刊

CHILDREN-BASEL
卷 9, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/children9020127

关键词

cancer; cardio-oncology; cardiovascular; oncology; pediatric

向作者/读者索取更多资源

The landscape of pediatric oncology has changed significantly, with improved survival rates due to advancements in chemotherapy and development of novel therapies. However, many targeted treatments can lead to cardiovascular pathologies. Data on prevention and treatment strategies for pediatric cardiac diseases are lacking, leading to practice variability. Future research should focus on prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and understanding the role of genetic susceptibility. Collaboration between pediatric cardiologists and oncologists is crucial for better understanding and preventing cardiac diseases in pediatric oncology patients.
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据